David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

Lymphoma

Stephen J. Schuster, MD

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor (Abstract 99).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Issues in Oncology

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida.

Moderator: Robert Rifkin, MD
Participants: Corey Cutler, MD; Pere Gascon, MD, PhD; Mark McCamish, MD, PhD

This program is supported by Sandoz Inc.

Aug

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events

Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital

Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?

Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer

Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses